Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
GlobeNewswire Inc.
•
•By Na
Jasper Therapeutics reported positive updated clinical data from its BEACON Phase 1b/2a study and open-label extension study of briquilimab for chronic spontaneous urticaria (CSU). The drug demonstrated rapid disease control with 67% of additional BEACON patients achieving complete response at 12 weeks and 75% of CSU participants in the extension study achieving complete response or well-controlled disease. Safety profile remained favorable with low-frequency, predominantly low-grade adverse events. The company plans to initiate a Phase 2b study in the second half of 2026.